Parkinson’s Disease — Clinical Documentation Guide (2026)

🔍 Definition

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of misfolded alpha-synuclein protein aggregates (Lewy bodies) in surviving neurons. The pathological hallmark is dopamine depletion in the nigrostriatal pathway, producing the cardinal motor features of the disease. According to the Parkinson’s Foundation, approximately 1 million people in the United States currently live with Parkinson’s disease, with nearly 90,000 new diagnoses each year.

For coding purposes, a critical distinction exists among three categories:

• Idiopathic (primary) Parkinson’s disease — coded to category G20.x. This is the most common form, representing approximately 85–90% of all parkinsonism cases, and arises from unknown etiology with characteristic Lewy body pathology.
• Secondary parkinsonism — coded to category G21.x. These are parkinsonian syndromes caused by identifiable external factors including drugs, toxins, vascular disease, or infection.
• Parkinson-plus syndromes (degenerative basal ganglia diseases) — coded to category G23.x. These atypical parkinsonisms include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and others. They differ clinically and have different RAF/HCC implications.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Cardinal Motor Features (TRAP Mnemonic)

• Tremor — Resting tremor (pill-rolling), 4–6 Hz frequency; asymmetric onset; suppressed by voluntary movement
• Rigidity — Cogwheel or lead-pipe resistance to passive movement; may present as shoulder pain
• Akinesia/Bradykinesia — Slowness of initiation and execution of movement; micrographia; hypomimia (masked face); hypophonia
• Postural instability — Impaired balance and righting reflexes; hallmark of later disease (Hoehn-Yahr stage 3+)

Motor Complications (Critical for FY2026 Code Selection)

• Motor fluctuations (“off” episodes) — Wearing-off at end of dose, unpredictable “on/off” switching, early morning akinesia; affects code selection for G20.A2 vs. G20.B2
• Levodopa-induced dyskinesia (LID) — Involuntary choreiform or dystonic movements during “on” periods; key clinical indicator for G20.B1/G20.B2 assignment
• Freezing of gait (FOG) — Sudden inability to initiate or continue walking; major fall risk

Non-Motor Features

• Autonomic dysfunction: Orthostatic hypotension, constipation (K59.00), urinary dysfunction including urinary incontinence (N39.41), sialorrhea, seborrhea
• Cognitive/neuropsychiatric: Mild cognitive impairment, Parkinson’s disease dementia (PDD) — coded with F02.x as manifestation; depression (F32.x/F33.x); anxiety; psychosis (hallucinations, delusions)
• Sleep disorders: REM sleep behavior disorder (RBD) — G47.52 (may precede motor onset by years); insomnia; excessive daytime sleepiness
• Sensory: Anosmia (often pre-motor symptom), pain, restless legs
• Dysphagia: R13.1x — aspiration risk; associated with aspiration pneumonia (J69.0), a major comorbidity requiring attention during inpatient stays
• Falls: W19.xxXA — high frequency, high injury risk; critical to document fall history and Hoehn-Yahr stage

Hoehn and Yahr Staging System

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

Parkinson’s disease primarily affects the substantia nigra pars compacta (SNpc), a midbrain nucleus responsible for producing dopamine that projects to the striatum (caudate nucleus and putamen) via the nigrostriatal pathway. Loss of approximately 60–80% of SNpc dopaminergic neurons is required before clinical motor symptoms emerge, reflecting the brain’s compensatory capacity.

Core Pathology

• Lewy bodies: Eosinophilic intracellular inclusions containing misfolded alpha-synuclein protein. Per the Parkinson’s Foundation, these aggregates disrupt neuronal function and are the pathological hallmark of both PD and Dementia with Lewy Bodies (DLB).
• Braak staging: Alpha-synuclein pathology spreads in a predictable pattern (Braak stages 1–6), beginning in the olfactory bulb and dorsal motor nucleus (explaining anosmia and autonomic symptoms pre-dating motor features), ascending to substantia nigra (motor symptoms), and eventually involving the neocortex (dementia).

Basal Ganglia Circuit Disruption

Normal motor control requires a balance between the direct pathway (facilitating movement, dopamine D1 receptor-mediated) and the indirect pathway (suppressing unwanted movement, dopamine D2 receptor-mediated). Dopamine depletion increases inhibitory output from the globus pallidus internus (GPi) and subthalamic nucleus (STN) to the thalamus, reducing thalamo-cortical activation and producing bradykinesia and rigidity. Deep brain stimulation targets the STN or GPi to modulate this abnormal inhibitory output.

Parkinson-Plus Syndromes: Key Pathological Differences

• PSP (G23.1): Tau protein accumulation (tauopathy); affects the subthalamic nucleus, globus pallidus, superior colliculus; explains vertical gaze palsy
• MSA (G23.2/G23.3): Alpha-synuclein oligodendroglial inclusions (glial cytoplasmic inclusions); involves striatonigral system (MSA-P) and olivopontocerebellar system (MSA-C)
• DLB (G31.83): Widespread cortical Lewy body pathology; overlaps with PD but dementia onset precedes or coincides with motor features

💊 Medication Impact / Treatment

Dopaminergic Pharmacotherapy

Levodopa combined with carbidopa (the decarboxylase inhibitor) remains the most effective symptomatic treatment. Levodopa-carbidopa intestinal gel (Duopa, HCPCS J7340) is indicated for advanced PD with severe motor fluctuations via continuous jejunal infusion. Per FDA labeling, motor fluctuation documentation is essential to justify Duopa therapy.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

Etiology/Manifestation Convention — Parkinson’s Disease with Dementia

Per the FY2026 ICD-10-CM Official Guidelines for Coding and Reporting (CMS), the etiology/manifestation convention is explicitly illustrated with Parkinson’s disease as an example. When dementia accompanies Parkinson’s disease:

1. The underlying etiology code from category G20.- (Parkinson’s disease) is sequenced first
2. The manifestation code from category F02.- (dementia in other diseases classified elsewhere) is sequenced second, in brackets in the Alphabetic Index

FY2026 G20 Subcode Structure — Dyskinesia and Fluctuations

Effective October 1, 2023 (FY2024) and continuing through FY2026, the single G20 code was expanded into five subcodes capturing motor complication status. As of the April 1, 2026 ICD-10-CM Index update, a documented diagnosis of “Parkinson’s disease” now directs coders to G20.A1 rather than the former path to G20.C:

Key Guidelines for Parkinson’s-Related Coding

• Code also dementia: When Parkinson’s disease is documented with dementia, use an additional code for F02.80 or F02.81x (with or without behavioral disturbance). Beginning FY2024, F02.81x has 6th-character expansion for behavioral disturbance type.
• Secondary parkinsonism: For G21.x codes, code also the adverse effect or underlying condition (e.g., adverse effect of drug code T code, or underlying disease code).
• Dementia with Lewy bodies (G31.83): Code also, when applicable, dementia with behavioral disturbance (F02.81x) or without behavioral disturbance (F02.80).
• REM sleep behavior disorder: G47.52 may be coded additionally and is clinically significant as a pre-motor PD marker.
• Dysphagia in PD: R13.1x is coded additionally; if aspiration pneumonia (J69.0) is documented, it should be coded as an additional diagnosis.
• Falls: W19.xxXA is an external cause code and requires at least one injury code; however W19 without resulting injury is commonly used for encounter documentation related to fall risk.
• Code specificity requirement: Per FY2026 Official Guidelines Section I.A, codes must be reported at the highest level of specificity documented. For G20, this means selecting the appropriate subcode (G20.A1, G20.A2, G20.B1, G20.B2, or G20.C) based on provider documentation of dyskinesia and motor fluctuations.

🔢 ICD-10-CM Code Set (FY2026)

Primary Parkinson’s Disease (G20.-) — FY2026 Subcodes

Secondary Parkinsonism (G21.-)

Degenerative Basal Ganglia Diseases / Parkinson-Plus (G23.-)

Lewy Body Dementia

Dementia Manifestation Codes (F02.-) — Sequence After G20.x or G31.83

Additional Secondary Diagnosis Codes

🔎 Indexing

The following index pathway changes are critical for FY2026 accurate code assignment, per the April 1, 2026 ICD-10-CM updates:

🏥 CPT (2026)

Deep Brain Stimulation (DBS) — Surgical Procedures

DBS is indicated for idiopathic Parkinson’s disease (G20.x) with inadequate medication response. Per the Boston Scientific 2026 DBS Reimbursement Guide and the Medtronic 2026 DBS Coding Guide, coverage requires idiopathic PD (G20.x). Non-idiopathic Parkinson’s or Parkinson-plus syndromes (G23.x) are contraindications to DBS coverage by most payers.

DBS Programming and Analysis

Physical, Speech, and Psychiatric Therapy Codes

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

💰 HCC / Risk Adjustment (v28)

CMS-HCC Model Version 28 (V28) became fully operative for Medicare Advantage Payment Year 2026 (100% V28, replacing the blended V24/V28 model). Per RAAPID Inc. and Smart Health Asia HCC analysis:

MS-DRG Mapping Notes

For inpatient encounters, Parkinson’s disease (G20.x) typically maps to:

• MDC 01 (Diseases and Disorders of the Nervous System)
• MS-DRG 056/057/058 — Degenerative nervous system disorders (with or without MCC/CC). DBS surgery maps to surgical DRGs in the nervous system chapter.
• MS-DRG 040/041/042 — Peripheral, cranial, and other nervous system procedures with implant (DBS lead/IPG surgery).
• Aspiration pneumonia complication (J69.0) as a CC/MCC may elevate DRG weight significantly.

✍️ CDI Query Templates

🧑‍⚕️ Treatments (Clinical)

Pharmacological Management

According to the American Academy of Neurology (AAN) guidelines for Parkinson’s disease, management is staged by disease progression:

• Early PD: Dopamine agonists (pramipexole, ropinirole, rotigotine) or levodopa/carbidopa for motor symptom control. MAO-B inhibitors (rasagiline, safinamide) as adjunctive or monotherapy in mild disease.
• Moderate PD with fluctuations: Levodopa dose optimization; addition of COMT inhibitors (entacapone, opicapone) or MAO-B inhibitors to extend levodopa effect. Rotigotine transdermal patch for continuous dopaminergic stimulation.
• Advanced PD (G20.B2): Duopa (carbidopa-levodopa intestinal gel, J7340) for continuous jejunal infusion; subcutaneous apomorphine (Apokyn) for acute “off” episodes; DBS evaluation when medications inadequate.
• Dyskinesia management: Amantadine extended-release (Gocovri, Osmolex ER) — FDA-approved for levodopa-induced dyskinesia; dose timing adjustments.
• Psychosis in PD: Reduce or stop anticholinergics, amantadine; use clozapine (with monitoring) or pimavanserin (Nuplazid) — the only FDA-approved agent for PD-related psychosis.
• PD dementia: Rivastigmine (FDA-approved for PDD) — the only cholinesterase inhibitor with a specific PDD indication.

Surgical Management

Deep brain stimulation (DBS) is the gold standard surgical treatment for idiopathic PD meeting criteria. Key surgical targets include:

• Subthalamic nucleus (STN): Most common target; effective for tremor, rigidity, bradykinesia, reduces medication requirements
• Globus pallidus internus (GPi): Preferred when dyskinesia is the predominant complication; may be better for patients with cognitive concerns
• Ventral intermediate nucleus of thalamus (Vim): Used primarily for tremor-dominant PD

DBS patient selection criteria per AAN/Movement Disorder Society: idiopathic PD diagnosis (G20.x), demonstrated levodopa responsiveness, absence of significant cognitive impairment, adequate social/caregiver support, Hoehn-Yahr stage 2–4 typically.

Rehabilitation Therapies

• LSVT BIG (CPT 97110, 97112): Evidence-based amplitude-oriented physical therapy designed for PD gait and movement; intensive outpatient program; per LSVT Global, improves motor function across all Hoehn-Yahr stages
• LSVT LOUD (CPT 92507): Intensive voice therapy targeting hypophonia and speech deficits; 16-session protocol; evidence base from multiple randomized controlled trials
• Exercise: High-intensity aerobic exercise (cycling, boxing-based programs like Rock Steady Boxing) shows neuroprotective and symptomatic benefits; refer to exercise as medicine framework
• Occupational therapy: ADL adaptation, home safety, driving evaluation, adaptive equipment

Management of Non-Motor Complications

• Constipation (K59.00): Polyethylene glycol (MiraLax), increased fiber, hydration; avoid bulk-forming agents without adequate hydration
• Orthostatic hypotension: Fludrocortisone, midodrine, droxidopa (Northera) — especially in MSA; compression stockings, salt supplementation
• Urinary incontinence (N39.41): Anticholinergics (with caution — cognitive effects); mirabegron (beta-3 agonist) preferred in PD; botulinum toxin for refractory cases
• REM sleep behavior disorder (G47.52): Clonazepam (low dose), melatonin; bed-safety measures; iron supplementation in some cases
• Depression (F32.x/F33.x): SNRIs (venlafaxine) or SSRIs; nortriptyline may improve both depression and pain; pramipexole has antidepressant properties

🎓 Patient Education / Summary

Parkinson’s disease is a lifelong, progressive condition. While there is currently no cure, significant quality-of-life improvements are achievable with optimal treatment. Key patient education points supported by the Parkinson’s Foundation and the American Parkinson Disease Association (APDA):

Understanding Your Diagnosis

• Parkinson’s disease is a brain condition caused by loss of dopamine-producing cells. It is not contagious and is not directly caused by anything you did.
• Parkinson’s progresses at different rates for different people. Many people live independently for years or decades after diagnosis.
• The disease affects movement (tremor, stiffness, slowness) but also many non-motor functions including sleep, digestion, mood, and cognition.

Medication Management

• Take levodopa/carbidopa on a strict schedule — timing relative to meals matters (high-protein meals can impair absorption).
• Never stop Parkinson’s medications suddenly without medical guidance — abrupt discontinuation can cause a life-threatening condition (neuroleptic malignant syndrome-like presentation).
• Report any involuntary movements (dyskinesia) or periods when medications seem less effective (“off” times) to your neurologist immediately — these may require medication adjustments and affect your diagnosis code.
• Avoid antipsychotic medications (haloperidol, risperidone, olanzapine) for behavioral symptoms unless supervised by your movement disorder specialist — these can dramatically worsen Parkinson’s symptoms.

Exercise and Lifestyle

• Regular aerobic exercise (walking, cycling, swimming, boxing-based programs) is one of the most effective tools for slowing functional decline. Aim for 150 minutes per week of moderate-intensity activity.
• LSVT BIG (physical therapy) and LSVT LOUD (speech therapy) are specialized, proven programs for Parkinson’s — ask your care team for a referral.
• Fall prevention is critical: remove home hazards (rugs, clutter), use nightlights, install grab bars, consider a walker or cane when balance is affected. Report all falls to your medical team.

When to Seek Emergency Care

• Sudden severe stiffness or inability to move combined with high fever — this may indicate a medication emergency
• Choking, difficulty swallowing liquids or solids — increased aspiration risk; seek speech therapy evaluation
• Sudden confusion or hallucinations — may indicate infection, medication issue, or dementia complication
• Fall with significant injury

Resources

• Parkinson’s Foundation — helpline 1-800-4PD-INFO, clinical guidelines, care centers
• American Parkinson Disease Association (APDA) — local chapters, support groups
• Michael J. Fox Foundation for Parkinson’s Research — research updates, clinical trial matching
• NINDS Parkinson’s Disease Information Page

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)